251 related articles for article (PubMed ID: 30525982)
1. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
[TBL] [Abstract][Full Text] [Related]
3. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
Lewis JR; Kerridge I; Lipworth W
J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
[TBL] [Abstract][Full Text] [Related]
4. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
Haas M; Hall J; Viney R; Gallego G
Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
[TBL] [Abstract][Full Text] [Related]
5. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
6. Translational health economics: The key to accountable adoption of in vitro diagnostic technologies.
Price CP; Wolstenholme J; McGinley P; St John A
Health Serv Manage Res; 2018 Feb; 31(1):43-50. PubMed ID: 29084478
[TBL] [Abstract][Full Text] [Related]
7. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness modelling in diagnostic imaging: a stepwise approach.
Sailer AM; van Zwam WH; Wildberger JE; Grutters JP
Eur Radiol; 2015 Dec; 25(12):3629-37. PubMed ID: 26003789
[TBL] [Abstract][Full Text] [Related]
9. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
10. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
11. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
Phillips KA; Douglas MP; Trosman JR; Marshall DA
Value Health; 2017 Jan; 20(1):47-53. PubMed ID: 28212968
[TBL] [Abstract][Full Text] [Related]
12. Uncertainties in real-world decisions on medical technologies.
Lu CY
Int J Clin Pract; 2014 Aug; 68(8):936-40. PubMed ID: 25074335
[TBL] [Abstract][Full Text] [Related]
13. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
[TBL] [Abstract][Full Text] [Related]
14. Development, implementation and evaluation of an evidence-based program for introduction of new health technologies and clinical practices in a local healthcare setting.
Harris C; Garrubba M; Allen K; King R; Kelly C; Thiagarajan M; Castleman B; Ramsey W; Farjou D
BMC Health Serv Res; 2015 Dec; 15():575. PubMed ID: 26707549
[TBL] [Abstract][Full Text] [Related]
15. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
16. Value of research and value of development in early assessments of new medical technologies.
Retèl VP; Grutters JP; van Harten WH; Joore MA
Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
[TBL] [Abstract][Full Text] [Related]
17. An introduction to the methods of cost-effectiveness analysis.
Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
19. Getting to 'smart' health care.
Clancy CM
Health Aff (Millwood); 2006; 25(6):w589-92. PubMed ID: 17090557
[TBL] [Abstract][Full Text] [Related]
20. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT).
Canestaro WJ; Pritchard DE; Garrison LP; Dubois R; Veenstra DL
J Manag Care Spec Pharm; 2015 Aug; 21(8):700-12. PubMed ID: 26233542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
